Phase I study of high-dose etoposide phosphate in man

Bone Marrow Transplantation

Volumn 18, Issue 5, 1996, Pages 851-856

  Fields, S Z ^a   Budman, D R ^b   Young, R R ^a   Kreis, W ^b   Ingram, R ^a   Schulman, P ^b   Cherny, R C ^a   Wright, J ^a   Behr, J ^b   Snow, C ^a   Schacter, L P ^c,d  

^a Regional Oncology Center   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

Etoposide phosphate; Pharmacokinetics; Phase I trial

Indexed keywords

CYTOTOXIC AGENT; ETOPOFOS; GRANULOCYTE COLONY STIMULATING FACTOR; PRODRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPHOSPHORYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 10544227759     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. O'Dwyer PL, Layland-Jones B, Alonso MT et al. Etoposide (VP-16-213): current status of an active anti-cancer drug. New Engl J Med 1985; 312: 692-700.
2. Herzig RH. High-dose etoposide and marrow transplantation. Cancer 1991; 67: 292-298.
3. Blume KG, Long GD, Negrin RS et al. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 (Suppl. 4): 9-10.
4. Brown RA, Herzig RH, Wolff SN et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76: 473-479.
5. Hudson MM, Weinstein HJ, Donaldson SS et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11: 1080-1084.
6. Chao NJ, Stein AS, Long GD et al. Busulfan/etoposide initial experiences with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia. Blood 1993; 81: 319-323.
7. Budman DR, Igwemezie LN, Behr JM et al. Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a five minute infusion on days 1, 3, 5. J Clin Oncol 1994; 12: 1902-1909.
8. Fields SZ, Igwemezie LN, Kaul S et al. Phase I study of etoposide phosphate 30 minute infusion days 1, 3, 5 in cancer patients. Clin Cancer Res 1995; 1: 23-28.
9. Igwemezie LN, Kaul S, Barbhaiya RH. Assessment of toxico-kinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. Pharm Res 1995; 12: 117-123.
10. Kreis W, Budman DR, Vinciguerra V et al. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 1996; 38: 378-384.
11. Postmus PE, Mulder NH, Sleijfer DT et al. High-dose etoposide for refractory malignancies: A phase I study. Cancer Treat Rep 1984; 68: 1471-1474.
12. Hande KR, Wedlund PJ, Noone RM et al. Pharmacokinetics of high dose etoposide (VP16-213) administered to cancer patients. Cancer Res 1984; 44: 379-382.
13. Köhl P, Köpler H, Schmidt L et al. Pharmacokinetics of high dose etoposide after short term infusion. Cancer Chemother Pharmacol 1992; 29: 316-320.
14. Schwinghammer TL, Fleming RA, Rosenfeld CS et al. Disposition of total and unbound etoposide following high dose therapy. Cancer Chemother Pharmacol 1993; 32: 273-278.
15. Newman EM, Doroshow JH, Forman SJ, Blume KG. Pharmacokinetics of high-dose etoposide. Pharmacol Ther 1988; 43: 561-564.